ARIAD Announces Initiation of Phase 1/2 Clinical Trial of AP32788, an Investigational Oral Inhibitor of EGFR and HER2, in Patients with Non-Small Cell Lung Cancer
Go back to ARIAD Announces Initiation of Phase 1/2 Clinical Trial of AP32788, an Investigational Oral Inhibitor of EGFR and HER2, in Patients with Non-Small Cell Lung Cancer| Ariad Pharmaceuticals, Inc. (NYSE: ARIA) | Delayed: 26.76 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $26.76 | 52 Week High | $14.34 | |||
| Open | $26.76 | 52 Week Low | $4.37 | |||
| Day High | $26.76 | P/E | N/A | |||
| Day Low | $26.76 | EPS | $-1.45 | |||
| Volume | 2 | |||||
